WVE

WVE

USD

Wave Life Sciences Ltd. Ordinary Shares

$8.010+0.000 (0.000%)

Reaalajas hind

Healthcare
Biotehnoloogia
Singapur

Hinnagraafik

Loading Chart...

Põhinäitajad

Turunäitajad
Ettevõtte fundamentaalnäitajad
Kauplemisstatistika

Turunäitajad

Avatud

$8.010

Kõrge

$8.270

Madal

$7.950

Maht

1.95M

Ettevõtte fundamentaalnäitajad

Turukapitalisatsioon

1.3B

Tööstusharu

Biotehnoloogia

Riik

Singapore

Kauplemisstatistika

Keskmine maht

2.52M

Börs

NGM

Valuuta

USD

52 nädala vahemik

Madal $5.28Praegune $8.010Kõrge $16.74

Seotud uudised

GlobeNewswire

Wave Life Sciences to Present Preclinical Data Supporting Therapeutic Potential of WVE-007 for Obesity at ObesityWeek® 2025

Presentation will highlight preclinical data supporting the potential of WVE-007 (INHBE GalNAc-siRNA) as a unique approach for the treatment of obesity designed to drive fat loss while preserving muscle mass with once or

Vaata rohkem
Wave Life Sciences to Present Preclinical Data Supporting Therapeutic Potential of WVE-007 for Obesity at ObesityWeek® 2025
GlobeNewswire

Wave Life Sciences Third Quarter 2025 Financial Results Scheduled for November 10, 2025

CAMBRIDGE, Mass., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (NASDAQ:WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, will

Vaata rohkem
Wave Life Sciences Third Quarter 2025 Financial Results Scheduled for November 10, 2025
GlobeNewswire

Correcting and Replacing Wave Life Sciences Announced Positive Target Engagement Data from INLIGHT Clinical Trial of WVE-007 for Obesity During Annual Research Day

This press release corrects and replaces the company's press release issued today, 10/29, at 4:15 p.m. ET in order to correct a typographical error in the first sub-bullet under "WVE-007 (GalNAc-siRNA)" – "Next steps."

Vaata rohkem
Correcting and Replacing Wave Life Sciences Announced Positive Target Engagement Data from INLIGHT Clinical Trial of WVE-007 for Obesity During Annual Research Day
GlobeNewswire

Wave Life Sciences Announced Positive Target Engagement Data from INLIGHT Clinical Trial of WVE-007 for Obesity During Annual Research Day

Dose-dependent mean reductions of Activin E of up to 85% one month post single dose of WVE-007 in INLIGHT clinical trial, exceeding levels that led to weight loss in preclinical models; WVE-007 is generally safe and well

Vaata rohkem
Wave Life Sciences Announced Positive Target Engagement Data from INLIGHT Clinical Trial of WVE-007 for Obesity During Annual Research Day
Analyst Upgrades

Clear Street Initiates Coverage On WAVE Life Sciences with Buy Rating, Announces Price Target of $22

Clear Street analyst Bill Maughan initiates coverage on WAVE Life Sciences with a Buy rating and announces Price Target of $22.

Vaata rohkem
Clear Street Initiates Coverage On WAVE Life Sciences with Buy Rating, Announces Price Target of $22

Püsi kursis

Määrake hinnateavitused, hankige tehisintellekti analüüsi uuendusi ja reaalajas turuuudiseid.